Shots:
- Insilico Medicine has entered into a strategic collaboration agreement with Takeda to advance clinically differentiated drug candidates across Takeda’s therapeutic areas, using Insilico’s Pharma.AI platform
- Insilico will lead AI-driven discovery, while Takeda will advance selected candidates through clinical development & hold exclusive worldwide rights to develop, manufacture, & commercialize resulting therapeutics
- As per the deal, Insilico will receive ~$60M in project initiation fees, near-term payments & milestones, and preclinical, clinical, commercial & sales milestone payments, representing the total deal value of ~$600M, plus tiered royalties
Ref: PRnewswire | Image: Insilico & Takeda | Press Release
Related News: Insilico Medicine and SK Biopharmaceuticals Sign AI-Driven Drug Discovery Deal Worth Up to $2.5B for Neuroimmune Disorders
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
